CTLA4 and myocarditis: Abatacept may be a promising candidate as an effective drug for reversing immune checkpoint inhibition in patients with corticosteroid-refractory myocarditis caused by both anti-CTLA-4 and anti-PD-1/PD-L1 antibodies (33), (51).